UCB said that Vimpat is available in three formulations, oral tablets, oral solution and IV injection, ensuring that patients can maintain consistent Vimpat treatment in any clinical setting.
Vimpat therapy can be initiated with either oral or IV administration, and patients can be converted between formulations, with equivalent dosing, without titration.
Ilo Leppik, director of epilepsy research and education program at University of Minnesota, said: “Having Vimpat available as an oral solution is very good news. There are many people for whom swallowing pills is difficult and the oral solution, which can be substituted milligram for milligram to the oral tablet, will be helpful to adults with swallowing difficulties.This will be particularly useful for elderly in nursing homes who may have gastric tubes in place.”
James Zackheim, medical director of CNS at UCB, said: “Long-term efficacy and safety data, and more than 50,000 global patient exposures, strengthens Vimpat’s role as an add-on therapy for the treatment of partial-onset seizures in adults.”